drugset / Trial / NCT01898806

Intralesional Steroids in the Treatment of Alopecia Areata

NCT01898806

RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims to determine the frequency of response to treatment with 3 concentrations of IL TAC, 2.5mg/ml, 5mg/ml or 10mg/ml as well as the duration of response and incidence of side effects compared to treatment with placebo (sterile saline solution). After the 1st 6 months, nonresponders or partial responders may be treated for 6 months with open label triamcinolone at the dose deemed appropriate by the investigator. The investigators will also perform skin biopsies of the scalp and draw blood at selected time points in order to examine the immunohistochemical/pathological response in scalp hair follicles and the systemic circulation to treatment with IL TAC for alopecia areata.

Timeline

Start
2011-09
Primary completion
2018-01
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Other / unclassified 2.5 mg/ml Other
Subject Triamcinolone Other / unclassified 5 mg/ml Other
Subject Triamcinolone Other / unclassified 10 mg/ml Other

Indications